LY3537031

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

OverweightAlcohol Use DisorderRenal ImpairmentImpairment

54 competitors in Overweight

#DrugCompanyPhaseTrials

1

Ozempic

Novo Nordisk

Approved

202

Mounjaro

Eli Lilly

Approved

163

Glucophage

EMD Serono

Approved

104

Taltz

Eli Lilly

Phase 3

15

Retatrutide

Eli Lilly

Phase 3

26

GZR18

GGan & Lee Pharmaceuticals.

Phase 3

67

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

48

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Phase 3

39

RAY1225

GGuangdong Raynovent Biotech Co., Ltd

Phase 3

110

Glucophage

EMD Serono

Phase 2

3Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Irritable Bowel Syndrome2 trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-C

Recruiting·Eli Lilly·Phase 2·NCT07545772·342 enrolled

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Brenipatide in the Treatment of Adult Participants With IBS-D

Recruiting·Eli Lilly·Phase 2·NCT07545759·531 enrolled

Alcohol Use Disorder2 trials

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Alcohol Use Disorder (RENEW-ALC-1)

Recruiting·Eli Lilly·Phase 3·NCT07219966·1,100 enrolled

A Phase 3, Multicenter, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Alcohol Use Disorder (RENEW-ALC-2)

Recruiting·Eli Lilly·Phase 3·NCT07219953·1,100 enrolled

Renal Impairment1 trial

A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment

Active, not recruiting·Eli Lilly·Phase 1·NCT07165015·32 enrolled

Overweight1 trial

A Study of LY3537031 in Overweight, Obese, and Healthy Participants

Active, not recruiting·Eli Lilly·Phase 1·NCT06606106·302 enrolled

ART1 trial

A Study of LY3537031 in Healthy Participants

Completed·Eli Lilly·Phase 1·NCT04648865·40 enrolled

2 more indications

Impairment1 trial

A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment

Recruiting·Eli Lilly·Phase 1·NCT07165002·32 enrolled

Unspecified1 trial

A Phase 1, 2-Part Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3537031 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3537031 in Healthy Participants

Completed·Eli Lilly·Phase 1·NCT07202871·47 enrolled

Details

Drug Info

Related News